Abstract 426P
Background
Breast cancer (BC) incidence is estimated to achieve over 3 million new cases and 1 million deaths by 2040. Beyond its physical toll, breast cancer detrimentally affects quality of life, imposing emotional, social, and financial burdens on patients and their families. Statins, commonly prescribed for managing cardiovascular health, have garnered attention for their potential role in breast cancer management. Emerging evidence suggests that statins possess anti-proliferative properties, which could impact breast cancer progression. Understanding the potential benefits of statin therapy in breast cancer patients is crucial for optimizing treatment strategies and improving outcomes.
Methods
We conducted a comprehensive search of medical databases including PubMed, Cochrane, and Scopus to identify pertinent studies focusing on the impact of Statin therapy in female breast cancer patients. We collected data on All-Cause Mortality, Recurrence Free Survival, Disease-Specific Mortality, and Disease-Free Survival. All statistical analyses were performed using the R statistical software (version 4.3.2).
Results
A total of 37 studies and 869.218 patients were included, of whom 136.809 (15,73%) was in the statins group and 745.080 (84%) was in the non-statin users. The majority of the individuals were male 2,278 (84,27%). Statin therapy was associated with a significantly reduced risk of all-cause mortality (HR 0.8635; 95% CI 0.8123–0.8179; P < 0.01; I2 = 93%), disease-specific mortality (HR 0.8462; 95% CI 0.7632–0.9382; P < 0.01; I2 = 97%), and recurrence (HR 0.7638; 95% CI 0.6652–0.8771; P = 0.01; I2 = 51%). Furthermore, statin use was associated with improved disease-free survival (HR 0.8415; 95% CI 0.4220–1.6780; P < 0.01; I2 = 74%).
Conclusions
Our meta-analysis suggests that statin therapy may confer beneficial effects on clinical outcomes in female breast cancer patients, including reduced all-cause mortality, disease-specific mortality, recurrence, and improved disease-free survival. However, further research is warranted to confirm these findings and elucidate the mechanisms underlying these associations.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
533P - First-line treatment in older patients with metastatic colorectal cancer: A large real-world study
Presenter: debora basile
Session: Poster session 15
534P - Second-line treatment in older patients with metastatic colorectal cancer: The ELECTRA study
Presenter: Alessia Cordua
Session: Poster session 15
535P - Safety and efficacy of first-line immune checkpoint inhibitors in elderly colorectal cancer patients: An Italian real-world multicenter experience
Presenter: Alessandra Boccaccino
Session: Poster session 15
536P - A randomized phase II/III trial comparing hepatectomy followed by mFOLFOX6 with hepatectomy alone for liver metastasis from colorectal cancer: Long-term results of JCOG0603
Presenter: Yukihide Kanemitsu
Session: Poster session 15
537P - Stereotactic ablative radiotherapy combined with fruquintinib and tislelizumab in metastatic colorectal cancer: Updated findings from a single-arm, prospective phase II trial (RIFLE)
Presenter: Yajiie Chen
Session: Poster session 15
538P - Combined hepatectomy with complete cytoreduction (CCS) and hyperthermic intraperitoneal chemotherapy (HIPEC) vs. HIPEC alone for metastatic colorectal cancer: A systematic review and meta-analysis
Presenter: Gabriele Lech
Session: Poster session 15
540P - Early treatment discontinuation (ETD) in dMMR/MSI-H metastastic colorectal cancer (mCRC) treated with immune checkpoint inhibitors (ICIs)
Presenter: Julien Taieb
Session: Poster session 15
541P - Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Subgroup efficacy and expanded safety analyses from CheckMate 8HW
Presenter: Thierry André
Session: Poster session 15